Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Clinical Trials

An Observational Study to Investigate the Effects of Rapid Transmeridian Travel

Completed

Conditions: Jet Lag Disorder

Interventions: Other: Transmeridian travel across multiple time zones

First Posted Date: 2015-09-25

Last Posted Date: 2018-06-26

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 119

Registration Number: NCT02560103

Locations: 🇺🇸
The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

Phase 2

Completed

Conditions: Smith-Magenis Syndrome
Circadian

Interventions: Drug: tasimelteon
Drug: placebo

First Posted Date: 2014-09-03

Last Posted Date: 2022-11-18

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT02231008

Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)

Conditions: Smith Magenis Syndrome

First Posted Date: 2014-07-02

Last Posted Date: 2016-03-25

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT02180451

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Phase 4

Completed

Conditions: Non-24-Hour-Sleep-Wake Disorder

Interventions: Drug: tasimelteon 20 mg capsule
Drug: tasimelteon 2 mg I.V.

First Posted Date: 2014-05-06

Last Posted Date: 2016-08-22

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT02130999

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

Phase 2

Completed

Conditions: Treatment-resistant Pruritus Associated With Atopic Dermatitis

Interventions: Drug: VLY-686
Drug: Placebo

First Posted Date: 2013-12-06

Last Posted Date: 2024-06-11

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 69

Registration Number: NCT02004041

Locations: 🇩🇪
Vanda Investigational Site, Munster, Germany

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

Phase 1

Completed

Conditions: Pruritus

Interventions: Drug: VLY-686
Drug: Placebo

First Posted Date: 2013-08-09

Last Posted Date: 2015-06-03

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01919944

Locations: 🇨🇭
Vanda Investigational Site, Arzo, Switzerland

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tasimelteon
Drug: Rifampin
Drug: Ketoconazole

First Posted Date: 2012-07-11

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01637636

Locations: 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol

Phase 1

Completed

Conditions: Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol

Interventions: Drug: tasimelteon
Drug: Placebo ethanol
Other: Placebo tasimelteon
Drug: Ethanol

First Posted Date: 2012-04-16

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT01578057

Locations: 🇨🇦
INC Research Toronto, Inc., Toronto, Ontario, Canada

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Fluvoxamine

First Posted Date: 2012-02-28

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01540500

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Tasimelteon

First Posted Date: 2012-02-06

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01526746

Locations: 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Home Terms & Conditions Privacy Policy